The company is now in the process of launching the next generation of nail fungus drugs, MOB-015The product is recommended for approval in 13 European countries, where Sweden and Ireland have already approved it. Moberg Pharma is currently conducting an issue of approximately SEK 100 million.
Se Moberg Pharma vd Anna Ljung Present the company via the banner below.
This material has been prepared for marketing purposes and is not and shall not be considered to constitute a prospectus under applicable laws and regulations. The full terms and conditions of the rights issue and further information about the company have been set out in a prospectus which was published and published on mobergpharma.se on August 14, 2023.
